News
Eli Lilly obesity pill disappoints and gives boost to arch-rival Novo Nordisk
Shares in US-based Lilly fell 14.2 per cent on the trial results, while stock in Danish arch-rival Novo Nordisk, the maker of the pioneering Ozempic weight-loss drug, rose 6.7 per cent. Novo Nordisk has been losing share to Lilly in the US in injectable weight-loss drugs.
A mum who admitted that she has illegally put her 13-year-old child on Mounjaro weight loss jabs has spoken out on why she ...
Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...
Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...
Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...
Clinical Trials Arena on MSN9d
Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmedEli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.
Scripps News on MSN3d
Eli Lilly's experimental Mounjaro pill showcases promising weight loss resultsEli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...
Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...
Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year guidance.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback